David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
David McIntosh, Founder and Chair of United Plasma Action, shared Umair Majid’s post on LinkedIn:
“This interesting post comes to us from a national Healthcare system that achieves levels of Immunoglobulin availability second to none and hugely more ample than the global average.
(Over 300gms per yr per thousand population, compared with less than 20gms.)
It seems particularly significant therefore that even with this comparatively very high availability, Canadian clinicians still regard Immunoglobulin as a scarce resource, to be husbanded with great care.
For the guidance of decision-makers in other lands, it will be interesting to see what conclusions emerge from analyses and comparisons of this kind.
Some tens of millions of patients’ lives may depend upon the outcome…”
Umair Majid, Benita M. Warmbold Research Fellow of Health System Innovation at Women’s College Hospital, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in PLOS One, adding:
“New Publication: How Physicians Manage Immunoglobulin in Canada.
I’m excited to share our new qualitative study published in PLOS One, conducted as part of my previous work with Canadian Blood Services.
This is one of the first studies to explore how Canadian physicians navigate prescribing immunoglobulin (Ig) amid rising global demand, supply pressures, and growing costs.
1. Prescribing Ig involves real uncertainty.
Even experienced specialists face open questions about why some patients respond better than others, optimal dosing, and treatment duration.
This stems not from a lack of training but from gaps in research on this complex biologic therapy.
2. Physicians see themselves as stewards of a scarce public resource.
Participants described weighing cost, considering alternatives, and acting as ‘reasonable gatekeepers’ of the blood supply while still putting patient needs first.
3. Advocacy is part of the job.
From engaging with hospital administration and government to navigating manufacturer-led patient support programs for subcutaneous Ig, physicians are deeply involved in the policy landscape that shapes access to treatment.
Our key message?
Rational, evidence-based prescribing matters, but a purely mechanistic approach may be inadequate.
Prescribing Ig is a socially situated practice shaped by patients, systems, and politics.
Thank you to co-authors Kelly Holloway and Quinn Grundy, and to the physicians who generously shared their time and insights.”
Title: Physician management of immunoglobulin in Canada: A qualitative study
Authors: Kelly Holloway, Umair Majid, Quinn Grundy
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution
-
Oct 12, 2026, 07:39Emmanuel J Favaloro: 100 Years of von Willebrand Disease and the Importance of Local Diagnosis and Management
-
Oct 12, 2026, 07:39Post-Stroke Fatigue Trajectories – 38% Recovered at 12 Months, While 16% Developed New Fatigue – International Journal of Stroke